Table 1.
Summary of Ab, CD4, and CD8 responses in ovarian cancer and melanoma patients
Ovarian (n = 22) | Melanoma (n = 25) | |
Antibody responses | ||
Baseline seropositives | 3 | 10 |
Baseline seronegatives | 19 | 15 |
Seroconversions | 8/19 (42%) | 5/15 (33%) |
Total posttreatment seropositives | 11/22 (50%) | 15/25 (60%) |
CD4+ T-cell responses | ||
Preexisting | 15/22 (68%) | 12/23 (52%) |
Postvaccination | 20/22 (91%) | 18/23 (78%) |
CD8+ T-cell responses | ||
Preexisting | 3/22 (14%) | 10/25 (40%) |
Postvaccination | 10/22 (45%) | 22/25 (88%) |